IL1B and neoplasm: Differences might be because of the means used to invalidate IL-1β, that is, KO mice with no IL-1β in the host, but with tumor cells producing IL-1β, or neutralizing antibody with a decrease, but not inhibition of both host and tumor IL-1β.